Compare Amgen, Inc. (AMGN) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Southern Copper Corp — how do they compare? Amgen, Inc. trades at $416.03 (market cap $224.14B), while Southern Copper Corp trades at $192.9 (market cap $164.21B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | SCCO | |
|---|---|---|
Market Cap | $224.14B | $164.21B |
Sector | Health | Basic Materials |
52-Week High | $417.20 | $218.85 |
52-Week Low | $271.18 | $93.70 |
Enterprise Value | $267.45B | $165.50B |
Dividend Yield | 2.43% | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
SCCO trades at $200.11, up 0.53% today, near its pivot point of $201. The stock exhibits strong profitability with a 35.87% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights its rally fueled by strong H1 results and higher copper prices, though production declines and premium valuations are noted concerns (Zacks Investment Research, 2026-08-11).
Outlook is mixed; robust earnings growth and AI-driven copper demand present upside, but high valuation ratios and analyst skepticism pose risks. The consensus price target of $153.64 suggests significant downside from current levels, indicating caution is warranted despite positive technical and fundamental trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
